Lung Cancer
- 1 May 2007
- journal article
- review article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 2 (5) , S24-S26
- https://doi.org/10.1097/01.jto.0000268637.10332.e3
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Pharmacogenomics: A reality or still a promise?Lung Cancer, 2006
- O-082 A randomized phase III trial comparing ionafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel (CP) in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)Lung Cancer, 2005
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2003
- Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancerOncogene, 2003
- Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2003
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Global cancer statistics in the year 2000The Lancet Oncology, 2001
- Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinomaCancer, 2001